Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores - PubMed (original) (raw)
. 2011 May 1;183(9):1207-14.
doi: 10.1164/rccm.201101-0110OC. Epub 2011 Mar 4.
Collaborators, Affiliations
- PMID: 21471084
- DOI: 10.1164/rccm.201101-0110OC
Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores
Sung-Han Kim et al. Am J Respir Crit Care Med. 2011.
Abstract
Rationale: Administration of adjuvant corticosteroids to patients with pandemic influenza A/H1N1 2009 (pH1N1) may reduce inflammation and improve outcomes.
Objectives: To assess the effect of adjuvant corticosteroid treatment on the outcome of critically ill patients with pH1N1 infection.
Methods: All adult patients with confirmed pH1N1 admitted to the intensive care unit of 28 hospitals in South Korea from September 2009 to February 2010 were enrolled. Patients with and without adjuvant corticosteroid treatment were retrospectively compared by two risk stratification models: (1) a retrospective cohort study that used propensity score analysis to adjust for confounding by treatment assignment and (2) a propensity-matched case-control study.
Measurements and main results: A total of 245 patients were enrolled in the cohort study, 107 of whom (44%) received adjuvant steroid treatment. In the cohort study, the 90-day mortality rate of patients given steroids (58%, 62 of 107) was significantly higher than that of those not given steroids (27%, 37 of 138) (P < 0.001). The steroid group was more likely to have superinfection such as secondary bacterial pneumonia or invasive fungal infection, and had more prolonged intensive care unit stays than the no-steroid group. Multivariate analysis indicated that steroid treatment was associated with increased 90-day mortality when independent predictors for 90-day mortality and propensity score were considered (adjusted odds ratio, 2.20; 95% confidence interval, 1.03-4.71). In the case-control study, the 90-day mortality rate in the steroid group was 54% (35 of 65) and 31% (20 of 65) in the no-steroid group (McNemar test, P = 0.004).
Conclusions: Adjuvant corticosteroids were significantly associated with higher mortality in critically ill patients with pH1N1 infection.
Comment in
- Pro: the illegitimate crusade against corticosteroids for severe H1N1 pneumonia.
Annane D. Annane D. Am J Respir Crit Care Med. 2011 May 1;183(9):1125-6. doi: 10.1164/rccm.201102-0345ED. Am J Respir Crit Care Med. 2011. PMID: 21531952 No abstract available. - Con: corticosteroids are not indicated for treatment of acute lung injury from H1N1 viral pneumonia.
Matthay MA, Liu KD. Matthay MA, et al. Am J Respir Crit Care Med. 2011 May 1;183(9):1127-8. doi: 10.1164/rccm.201103-0395ED. Am J Respir Crit Care Med. 2011. PMID: 21531953 Free PMC article. No abstract available. - Selective decontamination of the digestive tract may reinforce the efficacy of corticosteroids.
Silvestri L, Rommes JH, Petros AJ, Taylor N, van Saene HK. Silvestri L, et al. Am J Respir Crit Care Med. 2012 Feb 1;185(3):344. doi: 10.1164/ajrccm.185.3.344. Am J Respir Crit Care Med. 2012. PMID: 22298370 No abstract available.
Similar articles
- Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection.
Martin-Loeches I, Lisboa T, Rhodes A, Moreno RP, Silva E, Sprung C, Chiche JD, Barahona D, Villabon M, Balasini C, Pearse RM, Matos R, Rello J; ESICM H1N1 Registry Contributors. Martin-Loeches I, et al. Intensive Care Med. 2011 Feb;37(2):272-83. doi: 10.1007/s00134-010-2078-z. Epub 2010 Nov 24. Intensive Care Med. 2011. PMID: 21107529 Free PMC article. - The influence of corticosteroid treatment on the outcome of influenza A(H1N1pdm09)-related critical illness.
Delaney JW, Pinto R, Long J, Lamontagne F, Adhikari NK, Kumar A, Marshall JC, Cook DJ, Jouvet P, Ferguson ND, Griesdale D, Burry LD, Burns KE, Hutchison J, Mehta S, Menon K, Fowler RA; Canadian Critical Care Trials Group H1N1 Collaborative. Delaney JW, et al. Crit Care. 2016 Mar 30;20:75. doi: 10.1186/s13054-016-1230-8. Crit Care. 2016. PMID: 27036638 Free PMC article. - Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study.
Moreno G, Rodríguez A, Reyes LF, Gomez J, Sole-Violan J, Díaz E, Bodí M, Trefler S, Guardiola J, Yébenes JC, Soriano A, Garnacho-Montero J, Socias L, Del Valle Ortíz M, Correig E, Marín-Corral J, Vallverdú-Vidal M, Restrepo MI, Torres A, Martín-Loeches I; GETGAG Study Group. Moreno G, et al. Intensive Care Med. 2018 Sep;44(9):1470-1482. doi: 10.1007/s00134-018-5332-4. Epub 2018 Aug 3. Intensive Care Med. 2018. PMID: 30074052 Free PMC article. - Corticosteroids as adjunctive therapy in the treatment of influenza.
Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Rodrigo C, et al. Cochrane Database Syst Rev. 2016 Mar 7;3:CD010406. doi: 10.1002/14651858.CD010406.pub2. Cochrane Database Syst Rev. 2016. PMID: 26950335 Updated. Review. - Corticosteroids for the treatment of human infection with influenza virus: a systematic review and meta-analysis.
Yang JW, Fan LC, Miao XY, Mao B, Li MH, Lu HW, Liang S, Xu JF. Yang JW, et al. Clin Microbiol Infect. 2015 Oct;21(10):956-63. doi: 10.1016/j.cmi.2015.06.022. Epub 2015 Jun 27. Clin Microbiol Infect. 2015. PMID: 26123860 Review.
Cited by
- Association between glucocorticoid administration and outcomes in patients with ARDS based on the MIMIC-III database.
Lu Z, Tang Y, Liu M, Cao L, Chen H, Yu W, Sun Y. Lu Z, et al. Medicine (Baltimore). 2024 Aug 9;103(32):e39239. doi: 10.1097/MD.0000000000039239. Medicine (Baltimore). 2024. PMID: 39121259 Free PMC article. - A panel of janus kinase inhibitors identified with anti-inflammatory effects protect mice from lethal influenza virus infection.
Yu Y, Chen S, Zhang H, Duan Y, Li Z, Jiang L, Cao W, Peng Q, Chen X. Yu Y, et al. Antimicrob Agents Chemother. 2024 Apr 3;68(4):e0135023. doi: 10.1128/aac.01350-23. Epub 2024 Mar 12. Antimicrob Agents Chemother. 2024. PMID: 38470034 Free PMC article. - Corticosteroids in ARDS.
Kuperminc E, Heming N, Carlos M, Annane D. Kuperminc E, et al. J Clin Med. 2023 May 8;12(9):3340. doi: 10.3390/jcm12093340. J Clin Med. 2023. PMID: 37176780 Free PMC article. Review. - Analysis of risk factors of fungal superinfections in viral pneumonia patients: A systematic review and meta-analysis.
Ni H, Yu H, Lin Q, Zhong J, Sun W, Nie H. Ni H, et al. Immun Inflamm Dis. 2023 Jan;11(1):e760. doi: 10.1002/iid3.760. Immun Inflamm Dis. 2023. PMID: 36705416 Free PMC article. - Anti-inflammatory effects of medications used for viral infection-induced respiratory diseases.
Yamaya M, Kikuchi A, Sugawara M, Nishimura H. Yamaya M, et al. Respir Investig. 2023 Mar;61(2):270-283. doi: 10.1016/j.resinv.2022.11.002. Epub 2022 Dec 19. Respir Investig. 2023. PMID: 36543714 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical